These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 33486122)
1. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence. Falagas ME; Kyriakidou M; Voulgaris GL; Vokos F; Politi S; Kechagias KS J Glob Antimicrob Resist; 2021 Mar; 24():342-359. PubMed ID: 33486122 [TBL] [Abstract][Full Text] [Related]
2. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Ardebili A; Izanloo A; Rastegar M Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511 [TBL] [Abstract][Full Text] [Related]
3. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Falagas ME; Kasiakou SK Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195 [TBL] [Abstract][Full Text] [Related]
5. Colistin and polymyxin B in critical care. Michalopoulos A; Falagas ME Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952 [TBL] [Abstract][Full Text] [Related]
6. Rational use of intravenous polymyxin B and colistin: A review. Zakuan ZD; Suresh K Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826 [TBL] [Abstract][Full Text] [Related]
7. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. Zavascki AP; Goldani LZ; Li J; Nation RL J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146 [TBL] [Abstract][Full Text] [Related]
8. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609 [TBL] [Abstract][Full Text] [Related]
9. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Vardakas KZ; Falagas ME Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609 [TBL] [Abstract][Full Text] [Related]
10. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria. Doymaz MZ; Karaaslan E Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061 [No Abstract] [Full Text] [Related]
11. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections. Huang J; Tang YQ; Sun JY Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424 [TBL] [Abstract][Full Text] [Related]
12. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407 [TBL] [Abstract][Full Text] [Related]
13. Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. Siddiqui NU; Qamar FN; Jurair H; Haque A BMC Infect Dis; 2014 Nov; 14():626. PubMed ID: 25430979 [TBL] [Abstract][Full Text] [Related]
14. Polymyxins for CNS infections: Pharmacology and neurotoxicity. Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947 [TBL] [Abstract][Full Text] [Related]
15. Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis. Samal S; Samir SB; Patra SK; Rath A; Dash A; Nayak B; Mohanty D Indian J Crit Care Med; 2021 Feb; 25(2):199-206. PubMed ID: 33707900 [TBL] [Abstract][Full Text] [Related]
16. Rescuing the Last-Line Polymyxins: Achievements and Challenges. Nang SC; Azad MAK; Velkov T; Zhou QT; Li J Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412 [TBL] [Abstract][Full Text] [Related]
17. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Roberts KD; Zhu Y; Azad MAK; Han ML; Wang J; Wang L; Yu HH; Horne AS; Pinson JA; Rudd D; Voelcker NH; Patil NA; Zhao J; Jiang X; Lu J; Chen K; Lomovskaya O; Hecker SJ; Thompson PE; Nation RL; Dudley MN; Griffith DC; Velkov T; Li J Nat Commun; 2022 Mar; 13(1):1625. PubMed ID: 35338128 [TBL] [Abstract][Full Text] [Related]
18. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Ouderkirk JP; Nord JA; Turett GS; Kislak JW Antimicrob Agents Chemother; 2003 Aug; 47(8):2659-62. PubMed ID: 12878536 [TBL] [Abstract][Full Text] [Related]
19. Clinical Use of Polymyxin B. Rigatto MH; Falci DR; Zavascki AP Adv Exp Med Biol; 2019; 1145():197-218. PubMed ID: 31364080 [TBL] [Abstract][Full Text] [Related]
20. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Sisay M; Hagos B; Edessa D; Tadiwos Y; Mekuria AN Pharmacol Res; 2021 Jan; 163():105328. PubMed ID: 33276108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]